DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
03 janv. 2019 07h30 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
07 déc. 2018 07h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
12 nov. 2018 16h45 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list...
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
06 nov. 2018 17h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual...
FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
16 oct. 2018 16h27 HE
|
FibroGen, Inc
Roxadustat Phase 3 Clinical Results in Late-Breaking Clinical Trial Posters and Oral Presentation SAN FRANCISCO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading...
Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
01 oct. 2018 08h00 HE
|
FibroGen, Inc; Astellas Pharma Inc.
TOKYO and SAN FRANCISCO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B....
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
05 sept. 2018 08h00 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as...
American Kidney Fund Launches Comprehensive New Kidney Disease Education Portal
16 mai 2018 11h30 HE
|
American Kidney Fund
ROCKVILLE, Md., May 16, 2018 (GLOBE NEWSWIRE) -- The American Kidney Fund (AFK) today unveiled CKD Central, a new free online education portal offering comprehensive information and resources on...
DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
03 mai 2018 08h30 HE
|
DiaMedica Therapeutics Inc.
DiaMedica has received final minutes from Type B meeting with the US FDADiaMedica preparing to submit an IND to initiate DM199 clinical study in patients with chronic kidney disease in the US ...
DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
05 avr. 2018 07h15 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial...